Portal de investigación
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations(TROPION-Lung07).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
DAIICHI SANKYO, INC. C/O SYNEOS HEALTH UK LTD
Cita
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations(TROPION-Lung07). (DS1062-A-U303). DAIICHI SANKYO, INC. C/O SYNEOS HEALTH UK LTD. 2023IP:ÓSCAR JOSÉ JUAN VIDAL.